May 30, 2012 — Bayer Radiology & Interventional will showcase new device technologies at the annual meeting of the Society of Nuclear Medicine (SNM) in Miami, June 9-13. The new technology includes enhancements to the Intego PET (positron emission tomography) Infusion System, as well as developing platforms for controlled administration of molecular agents for SPECT (single photon emission computed tomography) and small animal imaging procedures.
In PET, the Medrad Intego System is a worldwide market leader and the only U.S. Food and Drug Administration (FDA) -cleared system for administration of 18F-FDG and 18F-NaF. Bayer has continued to innovate and evolve the Intego platform since its launch in 2008, including adding software features, expanding compatibility and indications, and significantly reducing the size of the device. At SNM, Bayer plans to demonstrate Certegra informatics solutions for Intego, including wireless integration to HIS (hospital information system), RIS (radiology information system) and PACS (picture archiving and communications system) that facilitate downloading the PET modality worklist as an infusion schedule and sending infusion results to PACS. This new capability will replace several manual processes, which in turn will streamline workflow and improve efficiency for PET imaging clinics.
"Automated, controlled injection of molecular agents not only has safety and workflow benefits for staff, it can lead to improvements in patient care and help clinicians and scientists unlock the potential of molecular medicine," said Doug Descalzi, senior director of molecular imaging devices for Bayer.
In addition the company will showcase developing technologies for controlled administration of low energy radiopharmaceuticals and for small animal molecular imaging.
For more information: www.bayerhealthcare.com
July 25, 2024 
